User:Mr. Ibrahem/Sotrovimab
 A vial of sotrovimab | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Spike protein of SARS-CoV-2 |
| Clinical data | |
| Trade names | Xevudy |
| Other names | VIR-7831, GSK4182136 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Legal status | |
| Legal status | |
Sotrovimab, sold under the brand name Xevudy, is a medication which was used to treat COVID-19 in people who do not need supplemental oxygen but are a high risk of getting severe disease.[1] In this group it decreased the need for hospitalization.[6] It; however, does not appear effective for Omicron BA.2 subvariant and is not recommended in regions were this makes up more than half of cases.[7][8][9] It is given by gradual injection into a vein.[1]
Common side effects include allergic reactions including anaphylaxis.[1] Anaphylaxis occurs in about 1 in 2,000 people.[1] Safety in pregnancy or breastfeeding is unclear.[5] It is a monoclonal antibody which attaches to the spike protein of SARS-CoV-2 making the virus unable to enter the body’s cells.[1]
Sotrovimab was approved for medical use in Europe in 2021.[1] It has Emergency Use Authorization (EUA) in the United States as of 2021.[5] In the United States it costs 2,100 USD per dose, with this amount paid by the the United States government.[10]
References[edit]
- ^ a b c d e f g h "Xevudy EPAR". European Medicines Agency (EMA). 15 December 2021. Archived from the original on 18 December 2021. Retrieved 17 December 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b "Xevudy". Therapeutic Goods Administration (TGA). 20 August 2021. Archived from the original on 18 September 2021. Retrieved 17 September 2021.
- ^ "TGA provisionally approves GlaxoSmithKline's COVID-19 treatment: sotrovimab (Xevudy)". Therapeutic Goods Administration (TGA) (Press release). 20 August 2021. Archived from the original on 4 September 2021. Retrieved 4 September 2021.
- ^ "COVID-19 treatment: GlaxoSmithKline Australia Pty Ltd, sotrovimab (Xevudy)". Therapeutic Goods Administration (TGA). 20 August 2021. Archived from the original on 23 October 2021. Retrieved 22 October 2021.
- ^ a b c "Sotrovimab injection, solution, concentrate". DailyMed. Archived from the original on 7 July 2021. Retrieved 15 June 2021.
- ^ "Treatments". www.bccdc.ca. Archived from the original on 9 October 2021. Retrieved 4 January 2022.
- ^ "Statement on Therapies for High-Risk, Nonhospitalized Patients". COVID-19 Treatment Guidelines. Archived from the original on 7 January 2022. Retrieved 6 January 2022.
- ^ Kreier, Freda (23 February 2022). "Will a rising Omicron variant scramble antibody treatments?". Nature: d41586–022–00419-6. doi:10.1038/d41586-022-00419-6.
- ^ "FDA updates Sotrovimab emergency use authorization". FDA. Archived from the original on 28 March 2022. Retrieved 30 March 2022.
- ^ "After slow start, demand for COVID monoclonal antibodies treatment skyrockets". USA Today. 25 August 2021. Archived from the original on 18 December 2021. Retrieved 18 December 2021.